On August 13, 2024, Senti Biosciences, Inc., a biotechnology company based in South San Francisco, California, announced its financial results for the second quarter ended June 30, 2024. The company, which is listed on the Nasdaq Capital Market under the trading symbol SNTI, reported a net loss of $11.2 million, or $2.45 per basic and diluted share. Research and development expenses increased to $9.2 million, primarily due to manufacturing costs for the company's wholly-owned programs. General and administrative expenses decreased to $4.2 million due to a reduction in headcount. Senti Biosciences also highlighted its compliance with the Nasdaq Minimum Bid Price Requirement, having regained compliance as the closing bid price of its common stock remained at $1.00 per share or greater for 10 consecutive business days. Additionally, the...Show More

On August 13, 2024, Senti Biosciences, Inc., a biotechnology company based in South San Francisco, California, announced its financial results for the second quarter ended June 30, 2024. The company, which is listed on the Nasdaq Capital Market under the trading symbol SNTI, reported a net loss of $11.2 million, or $2.45 per basic and diluted share. Research and development expenses increased to $9.2 million, primarily due to manufacturing costs for the company's wholly-owned programs. General and administrative expenses decreased to $4.2 million due to a reduction in headcount. Senti Biosciences also highlighted its compliance with the Nasdaq Minimum Bid Price Requirement, having regained compliance as the closing bid price of its common stock remained at $1.00 per share or greater for 10 consecutive business days. Additionally, the company announced the commencement of an $8 million grant award from the California Institute for Regenerative Medicines (CIRM) to support the clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The Phase 1 clinical trial of SENTI-202 is currently enrolling patients, with initial efficacy data expected by the end of 2024. Senti Biosciences also plans to initiate a pilot trial of SENTI-301A for the treatment of hepatocellular carcinoma (HCC) in China through a partnership with Celest later in the year.